BioSpace News Archive

CytoReason announced an extension of its multi-year partnership with Pfizer to use CytoReason’s artificial intelligence technology for Pfizer’s drug development programs.

Elicio Therapeutics announced that it has been awarded a $2.8 million grant from the Gastro-Intestinal Research Foundation in Chicago to fund research for two therapeutic cancer vaccines.

Eargo, Inc. announced that it had begun its proxy solicitation for the 2022 Annual Meeting of the Stockholders to be held on Wednesday, October 12, 2022 at 11 A.M. Pacific Time.

Alimera Sciences, Inc. announces that Alimera Sciences Europe Limited, its Ireland-based European subsidiary, has been granted reimbursement for ILUVIEN ® 0.19 mg sustained release intravitreal implant for non-infectious uveitis affecting the posterior segment in Ireland.

Humacyte, Inc. announced the appointments of two distinguished healthcare professionals to the Company’s Board of Directors and leadership team.

electroCore, Inc., a commercial-stage bioelectronic medicine company, announced its plans to hold its fiscal year 2022 annual meeting of stockholders on Friday, December 2, 2022.

MiMedx Group, Inc., a transformational placental biologics company, announced the launch of AXIOFILL™, an Extracellular Matrix Particulate product derived from human placental tissue.

Medtronic plc announced the LINQ II™ Insertable Cardiac Monitor system is the first-and-only ICM to receive 510 clearance by the U.S. Food and Drug Administration for use in pediatric patients over the age of 2 who have heart rhythm abnormalities and require long-term, continuous monitoring.

Xpira Pharmaceuticals (“Xpira” or “the Company”), a leading developer of next-generation psychedelic medicines for the treatment of eating disorders, is pleased to announce has obtained approval from the United States Food and Drug Administration (“FDA”) for its first Investigational New Drug (“IND”) application.

Atavistik Bio announced the formation of its Scientific Advisory Board (SAB).